Should also point out, although I'm guessing obvious to the current contributors on this forum, that Scott's guidance made on the 12/10 of USD$14M- $16M was for FY22. This is a US business, and FY 22 ended on 1/1/23. In other words the guidance was only for the remaining 2.5 months of the financial year. The half yearly was $7.1M.
The yearly report is due on 1/3/2023, which will confirm the FY22 revenue.
However, I'm hoping on a commentary ( guidance ) on FY23 revenue at the same time, somewhere around USD$25M ( +40% YoY ), leaving room to over deliver. And there has been commentary on building a stronger business around consumables/spare parts ( as mentioned by @RudiV ). This delivers many benefits .. improves cash flow, better margins, removes revenue "lumpiness".
The quarterly on 1st Feb ... I'm actually hoping that the new CFO may have used some initiative and offered incentives to customers of tools despatched in Q4 for early payment ... which may deliver better than expected receipts.
Let's see.
All IMO
- Forums
- ASX - By Stock
- RVS
- General Discussion
General Discussion, page-125
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RVS (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.73M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RVS (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online